Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $8.83 Average PT from Brokerages

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been given an average rating of “Buy” by the ten research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $8.8333.

A number of brokerages have commented on AQST. Piper Sandler upped their price objective on Aquestive Therapeutics from $5.00 to $8.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, January 21st. JMP Securities raised their price objective on Aquestive Therapeutics from $9.00 to $12.00 and gave the stock a “market outperform” rating in a research note on Thursday, October 9th. Finally, Citigroup reiterated an “outperform” rating on shares of Aquestive Therapeutics in a research report on Thursday, October 9th.

Aquestive Therapeutics Price Performance

Shares of AQST opened at $3.47 on Friday. The company has a market capitalization of $423.34 million, a price-to-earnings ratio of -4.89 and a beta of 1.66. The business’s 50-day moving average is $5.41 and its 200-day moving average is $5.24. Aquestive Therapeutics has a fifty-two week low of $2.12 and a fifty-two week high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The firm had revenue of $12.81 million during the quarter, compared to analyst estimates of $12.94 million. Equities research analysts expect that Aquestive Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of AQST. Arcataur Capital Management LLC purchased a new position in shares of Aquestive Therapeutics during the 4th quarter valued at approximately $239,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Aquestive Therapeutics during the fourth quarter worth $420,000. MBM Wealth Consultants LLC acquired a new stake in Aquestive Therapeutics during the fourth quarter valued at $109,000. Sugar Maple Asset Management LLC increased its holdings in Aquestive Therapeutics by 357.1% in the fourth quarter. Sugar Maple Asset Management LLC now owns 54,850 shares of the company’s stock valued at $354,000 after buying an additional 42,850 shares in the last quarter. Finally, Aberdeen Group plc raised its position in shares of Aquestive Therapeutics by 29.5% in the fourth quarter. Aberdeen Group plc now owns 809,203 shares of the company’s stock worth $5,227,000 after acquiring an additional 184,203 shares during the period. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.